Recently, CARA therapeutics completed a phase II clinical trial for an oral formulation of the peripherally restricted KOR agonist CR845 (difelikefalin) for the treatment of pruritus associated with patients that have atopic dermatitis (trial number NCT04018027). This evidence concerns the gene OPRK1 and atopic eczema.